JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M003259200 on May 4, 2000

J. Biol. Chem., Vol. 275, Issue 29, 22300-22304, July 21, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/29/22300    most recent
M003259200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abraham, D.
Right arrow Articles by Baccarini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abraham, D.
Right arrow Articles by Baccarini, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation*

Dietmar AbrahamDagger §, Klaus PodarDagger §, Margit PacherDagger , Markus KubicekDagger , Natascha WelzelDagger , Brian A. Hemmings, Stephen M. Dilworth||, Harald Mischak**, Walter KolchDagger Dagger , and Manuela BaccariniDagger §§

From the Dagger  Vienna Biocenter, Institute of Microbiology and Genetics, Dr. Bohr Gasse 9, A 1030 Vienna, Austria,  Friedrich-Miescher-Institute, Maulbeerstrasse 66, CH 4058 Basel, Switzerland, the || Department of Metabolic Medicine, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom, the ** Department of Nephrology, Hannover Medical School, Karl-Neuberg Strasse, D-30625 Hannover, Germany, and Dagger Dagger  CRC Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom

Received for publication, April 17, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Raf-1 kinase plays a key role in relaying proliferation signals elicited by mitogens or oncogenes. Raf-1 is regulated by complex and incompletely understood mechanisms including phosphorylation. A number of studies have indicated that phosphorylation of serines 259 and 621 can inhibit the Raf-1 kinase. We show that both serines are hypophosphorylated during early mitogenic stimulation and that hypophosphorylation correlates with peak Raf-1 activation. Concentrations of okadaic acid that selectively inhibit protein phosphatase 2A (PP2A) induce phosphorylation of these residues and prevent maximal activation of the Raf-1 kinase. This effect is mediated via phosphorylation of serine 259. The PP2A core heterodimer forms complexes with Raf-1 in vivo and in vitro. These data identify PP2A as a positive regulator of Raf-1 activation and are the first indication that PP2A may support the activation of an associated kinase.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Raf-1 kinase is an important intermediate in the transduction of proliferative signals, and its activation may be a key event in the development of a wide range of tumors (1). Activated Raf-1 can regulate the mitogen-activated protein kinase network by phosphorylating and activating MEK1; within the mitogen-activated protein kinase cascade, Raf interacts physically with MEK-1 via its kinase domain and with GTP-loaded Ras via its N terminus (2). Activated Ras is the best studied activator of Raf-1. It binds to Raf-1 with high affinity and mediates its translocation from the cytosol to the plasma membrane, where activation takes place (3, 4). Artificial tethering of Raf-1 to the cell membrane results in partial activation, which can be further enhanced by mitogenic stimulation, suggesting that at the cell membrane Raf-1 is exposed to both constitutive and mitogen-regulated activators (5-8).

Mitogenic stimulation of cells typically induces hyperphosphorylation of Raf-1 and a retardation of its migration on SDS gels. This hyperphosphorylation correlates with the down-regulation of Raf-1 kinase activity (9, 10) and may be implemented by a negative feedback mechanism depending on MEK activity (10, 11). Serines 43, 621, and 259 are phosphorylated in resting fibroblasts, albeit to different degrees (12). Phosphorylation of all three residues has been implicated in the negative regulation of Raf-1. Phosphorylation of serine 43 interferes with Ras binding and consequently with Ras-mediated activation (3). Phosphorylated serine 259 and serine 621 represent binding sites for 14-3-3 adaptor proteins (13, 14), whose function in Raf-1 activation is controversial. While bivalent binding to Ser259 and Ser621 has been suggested to maintain Raf-1 in an inactive conformation (15, 16), reversible association with 14-3-3 facilitates Ras-dependent activation in vivo and in vitro (17). In particular, binding to the Ser(P)621 site appears to be necessary for kinase activity (16, 18), a finding that contrasts with the studies indicating that phosphorylation of this site by PKA in vitro is inhibitory (19). Therefore, the significance of Ser621 phosphorylation is still in question. Its investigation is hampered by the fact that Ser621 is essential for the catalytic function of Raf-1 and cannot be replaced by other amino acids without loss of kinase activity (19, 20). Serine 259 can be phosphorylated by protein kinase B, another Ras effector activated in parallel with Raf, and this phosphorylation correlates with the down-regulation of kinase activity (21). Consistent with an inhibitory role of Ser(P)259, mutation of this residue moderately activates the Raf-1 kinase in cultured cells (16, 22); the corresponding point mutants display a gain of function phenotype in Drosophila (15, 20). Taken together, these data raise the possibility that dephosphorylation of negative regulatory residues plays a role in Raf-1 activation.

Protein phosphatase 2A (PP2A) is a major form of serine/threonine phosphatase involved in the regulation of signal transduction, growth, and development (23). This class of enzymes consists of a heterotrimer that exists in multiple forms. The core components of all trimeric forms are the 36-kDa catalytic subunit (PP2AC) and the 65-kDa regulatory subunit (A subunit, PR65). This core heterodimer is ubiquitous, and it forms complexes with "variable" subunits of cellular origin (some of which are expressed in a tissue- and/or development-restricted manner) as well as with transforming viral antigens (24-26). Association with variable subunits of cellular and viral origin occurs via the N-terminal leucine-rich repeats of PR65 (27) and confers distinct properties to the enzyme (28). Recently, PP2A has been shown to form a complex with Ca2+/calmodulin-dependent protein kinase IV (29) as well as with PAK1, PAK3, and p70 S6 kinase (30). The isolated catalytic subunit can associate with casein kinase 2alpha (31). Where investigated (29), PP2A has been shown to contribute to the inactivation of the associated kinase. Here we show that the PP2A inhibitor okadaic acid inhibits full fledged Raf-1 activation. This effect is mediated by a change in the phosphorylation of Ser259 of Raf-1. In addition, Raf-1 forms stable complexes with PP2A heterodimers. Our results are the first indication that PP2A may support the activation of an associated kinase and highlight the intimate relationship between kinases and phosphatases, which we are just beginning to understand.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Cell Culture, Transfection, and Growth Factor Stimulation-- BAC-1.2F5 cells (32) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 0.63 nM purified mouse recombinant mitogen colony-stimulating factor-1 (CSF-1) or 15% L-cell conditioned medium (33) as a source of murine CSF-1. COS-1 and COS-7 cells were grown in RPMI 1640 or Dulbecco's modified Eagle's medium supplemented with glutamine and 10% fetal calf serum. COS cells were transfected by electroporation (0.5-1 × 107 cells/cuvette, 240 V, 960 microfarads, 10 µg of plasmid DNA). The plasmids used were the pCMV5 vector, pCMV.HAcatalpha (amino acid 9 to the stop of human PP2ACalpha cloned downstream of a HA tag in pCMV), PRC/CMV.HA65a (amino acid 3 to the stop of human PR65a cloned downstream of a HA tag in pRC/CMV), pCMV-HA-ERK (courtesy of Michael Karin, UCSD), pCMV5Raf-1, and a S259A Raf-1 mutant (pCMV5-S259A). Cells were harvested 2 days after transfection. Under these conditions, protein expression increased linearly between 1 and 10 µg of transfected plasmid DNA. Confluent cultures were starved for 18 h prior to stimulation with recombinant CSF-1 (BAC-1.2F5 cells, 6.3 nM mouse recombinant CSF-1 or 63 nM human recombinant CSF-1 (Chiron Co.) or EGF (COS-1, 33 nM, 10 min). In selected experiments, cells were incubated with okadaic acid (100 nM, 45 min) prior to growth factor stimulation.

Monoclonal Antibody Production-- N-terminal His6-tagged human PP2AC was expressed in the bacterial strain M15[pREP4], and the fusion polypeptide was purified by Ni2+-nitrilotriacetic acid chromatography (Qiagen). Balb/c × CBA F1 mice (~3 months old) were immunized by subcutaneous injection with 100 µg of bacterially expressed PP2AC fusion protein emulsified with an equal volume of Titremax Gold (CytRx Corp.). The immunization was repeated four times at three monthly intervals, and then the mice rested for 6 months. A further 100 µg of fusion protein in phosphate-buffered saline plus 0.1% SDS was injected intraperitoneally at 6 and 3 days prior to sacrifice. Hybridoma lines were then established by fusing splenocytes from the immunized animal with the myeloma line Sp2/0-Ag14 by polyethylene glycol treatment and conventional procedures. Cell lines were screened for antibody production by a modified dot blot procedure using the bacterially expressed fusion protein (34) and cloned three times before tissue culture fluid containing the monoclonal antibody was harvested. Clone F2.8F5 was typed as an IgG2K species using Isotype strips (Roche Molecular Biochemicals) and confirmed as specific for PP2AC by Western blot analysis using total cell lysates. Using deletion mutants of PP2Ac (35), the epitope has been mapped close to the C-terminal end of PP2AC.

Cell Lysis, Immunoprecipitation, and Western Blotting-- Cells were lysed in solubilization buffer (10 mM Tris-Cl, 50 mM NaCl, 1% Triton X-100, 30 mM sodium pyrophosphate, 100 µM Na3VO4, 1 mM phenylmethylsulfonyl fluoride). Insoluble material was removed by centrifugation (15,000 rpm, 30 min, 4 °C). Immunoprecipitation was performed exactly as described previously (36). A rabbit polyclonal antiserum raised against a carboxyl-terminal peptide of v-raf (SP63; CTLTTSPRLPVF) was used to immunoprecipitate Raf-1 molecules. A mouse monoclonal antibody against PP2AC (F2 8F5) was used to immunoprecipitate PP2A. HA-tagged PR65alpha and PP2AC were immunoprecipitated with the HA-epitope-specific monoclonal antibody 12CA5. Immunocomplexes were collected following incubation (1-3 h at 4 °C) with protein A-Sepharose beads (Sigma). For Western blotting, cell lysates (25 µg/lane) or immunoprecipitates were separated by 7.5% SDS-PAGE prior to electrophoretic transfer onto Hybond C super (Amersham Pharmacia Biotech). The blots were probed with rabbit polyclonal antisera directed against Raf-1, PP2AC (antibody C1-20), PR65alpha (37), p55alpha and -beta (38), or p72 plus p130 (39) or with monoclonal antibodies against Raf-1 (PBB.1; Ref. 40), PP2AC (F2 8F5), or PR 65 (C5 9E10) prior to incubation with horseradish peroxidase-conjugated secondary antibodies and exposure to the ECL substrate. All blotting reagents were from Amersham Pharmacia Biotech. The blots were stripped according to the manufacturer's instruction.

Assay of Kinase and Phosphatase Activity-- Raf-1 kinase activity was measured as the ability of immunoisolated Raf-1 to phosphorylate recombinant, catalytically inactive MEK-1 (MEK-) or to activate recombinant MEK-1 in coupled assays using MBP (41) as the end point of the assay.

Protein Purification and Pull-down Assays-- The GST-Raf-1 fusions used in this study have been previously described (42). The proteins were expressed by standard techniques in the baculovirus Sf9 cell system and purified as described previously (43) with the exception that 1% Triton X-100 was added before binding to GST-agarose. For pull-down assays, 100-200 ng of GST-Raf-1 fusion proteins were incubated with either 1 mg of whole cell lysates or 200 ng of purified heterodimer, PR65alpha , or PP2AC for 3-6 h at 4 °C. The complexes were recovered by centrifugation and washed in solubilization buffer containing 0.03% SDS, 10 mM dithiothreitol, 0.5 M NaCl prior to Western blot analysis. PP2A heterodimer used in this study was provided by Prof. J. Goris (Leuven, Belgium). Catalytic subunit of PP2A was kindly provided by Dr. Lisa Ballou (I.M.P., Vienna). Both forms of the enzyme were purified from rabbit skeletal muscle (44). Recombinant PR65alpha was kindly provided by Dr. P. Turowski.

In Vivo Labeling of Cells and Phosphotryptic Peptide Mapping-- 32P-Labeling of cells was performed as described previously (36). Cell lysis and immunoprecipitation of Raf-1 proteins were performed as described above. 32P-Labeled proteins were resolved by 7.5% SDS-PAGE, extracted from the gels, and subjected to digestion with sequencing grade trypsin (Promega) according to the manufacturer's instructions prior to phosphopeptide mapping. Tryptic peptides were separated in the first dimension by electrophoresis using pH 8.9 buffer and in the second dimension (chromatography) using a buffer containing n-butanol/pyridine/acetic acid/water (12:10:3:15). Chromatography was allowed to proceed for 20 h. The amount of Raf-1 contained in the immunoprecipitates used for the mapping of the phosphotryptic peptides was determined by immunoblotting an aliquot of the immunoprecipitates, and it was equal in all samples. Phosphotryptic peptide mapping was repeated twice with comparable results.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The PP2A Inhibitor Okadaic Acid Decreases Mitogen-induced Raf-1 Activation and Dephosphorylation: Role of Ser259-- We have studied Raf-1 phosphorylation and activation in BAC-1.2F5 macrophages stimulated by CSF-1 (45, 46). The addition of CSF-1 to quiescent BAC-1.2F5 cells induced robust and transient activation of Raf-1 (Fig. 1A; Ref. 45). Peak (16-fold) Raf-1 activation correlated with the transient dephosphorylation of serine 621, the main residue phosphorylated in quiescent macrophages (Fig. 1B, b). Conversely, the decay of Raf-1 activity to a 4-fold stimulation 15 min post-CSF-1 treatment was accompanied by the hyperphosphorylation of serines 43 and 621. A number of minor yet unidentified residues (spots 2-4) as well as Ser259 (Fig. 1B, c) were also phosphorylated at this time. Pretreatment with okadaic acid (100 nM; at this concentration a specific inhibitor of PP2A but not PP1alpha (47)), caused a slight increase in basal kinase activity (2-fold) and in Raf-1 phosphorylation in general. Notably, both the peptide pattern and the amount of activity associated with the Raf-1 immunoprecipitates are identical in cells treated with okadaic acid alone and in cells treated with CSF-1 for 15 min (Fig. 1, A and B, compare c and d). This suggests that both positive and negative regulatory phosphorylation sites are targets of an okadaic acid-sensitive phosphatase and that the balance between phosphorylation of the positive and negative regulatory sites determines the extent of Raf-1 activation. Remarkably, in the presence of okadaic acid, maximal Raf-1 stimulation by CSF-1 was prevented, and only a moderate (5-6-fold) activation could be obtained. Inhibition of early serine 621 dephosphorylation and hyperphosphorylation of several other sites (most prominently serine 259) could be observed concomitantly. Phosphorylation increased further after 15 min of CSF-1 stimulation; by this time, Raf-1 activation had decayed despite the continuous presence of the phosphatase inhibitor (Fig. 1, A and B). Although these changes are complex, it can be appreciated that Ser259 and Ser621 are less phosphorylated (hypophosphorylated) in cells treated with CSF-1 alone than in cells treated with mitogen plus okadaic acid and that this "hypophosphorylation" correlates with maximal kinase activation. Thus, an okadaic acid-sensitive phosphatase is involved in Raf-1 dephosphorylation and activation in macrophages.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Dephosphorylation of selected residues correlates with Raf-1 kinase activation in mitogen-treated macrophages. A, quiescent BAC-1.2F5 cells were left untreated (open circles) or were pretreated with okadaic acid (100 nM, 45 min; closed squares) prior to stimulation with 6.3 nM CSF-1 for the time periods indicated. The kinase activity of Raf-1 immunoprecipitates was measured in a coupled assay. The results are expressed as cpm incorporated into the substrate. B, phosphotryptic peptide maps of Raf-1 immunoprecipitated from 32P-labeled macrophages. The immunoprecipitates in d-f are from okadaic acid (OA)-pretreated cells. a and d, quiescent BAC-1.2F5 cells; b and e, cells stimulated with CSF-1 for 0.5 min; c and f, cells stimulated with CSF-1 for 15 min prior to cell lysis and Raf-1 immunoprecipitation. The scheme shows the positions of Ser43-, Ser259-, and Ser621-containing peptides, as well as of spot 1 (Ser621 partial digest) and of the unidentified peptides 2-4. Phosphopeptides were identified by co-migration with corresponding synthetic peptides phosphorylated by PKA in vitro and by direct comparison with Raf-1 phosphorylation site mutants expressed in COS-1 cells (not shown). Ser259 shows a slightly anomalous migration in c. The table shows the radioactivity in the peptides quantitated using a Fuji phosphor imager and expressed as arbitrary units. The amount of Raf-1 contained in the immunoprecipitates used for the mapping of the phosphotryptic peptides was determined by immunoblotting an aliquot of the immunoprecipitates, and it was equal in all samples. Phosphotryptic peptide mapping was repeated twice with comparable results.

To determine whether okadaic acid influenced Raf-1 stimulation by receptor tyrosine kinases other than the CSF-1 receptor, we analyzed the effect of the inhibitor on COS-1 cells stimulated with EGF. In agreement with the data shown in Fig. 1A, okadaic acid significantly decreased EGF-mediated activation of wild type Raf-1 (Fig. 2A). To assess whether this effect depended on Ser259, COS-1 cells transfected with a Ser259 right-arrow Ala Raf-1 mutant (RafS259A) were treated with EGF in the presence or absence of okadaic acid. As described previously (12, 15, 16, 20, 22), the basal activity of RafS259A was modestly increased with respect to wild type Raf-1. EGF efficiently stimulated RafS259A, but in contrast with the wild type, activation of RafS259A was not decreased by pretreatment with okadaic acid (Fig. 2B). These data confirm the importance of the okadaic acid-sensitive phosphatase in Raf-1 activation by receptor tyrosine kinases and identify Ser259 as the Raf-1 site relevant for activation. The effect of okadaic acid on the activation of wild type Raf-1 in EGF-treated COS-1 cells was less dramatic than the one observed in BAC-1.2F5 macrophages stimulated by CSF-1. It is possible that the importance of dephosphorylation in Raf-1 activation may vary depending on the cell type; alternatively, Raf-1 overexpression might adversely affect the outcome of the experiment, as is often the case when multienzyme complexes are involved (see below).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   EGF-stimulated activation of wild type Raf-1, but not of a S259A Raf-1 mutant, is decreased by okadaic acid in COS-1 cells. COS-1 cells were transfected with a vector encoding human wild type Raf-1 (pCMV5c-raf) or S259A Raf-1 mutant (pCMV5-S259A). 48 h after transfection, cells were treated with okadaic acid (100 nM, 45 min) prior to stimulation with EGF (33 nM, 10 min), lysis, and immunoprecipitation. Raf-1 immunoprecipitates (duplicates) were assayed for kinase activity in a coupled assay. The amount of Raf-1 in the immune complexes was determined by immunoblotting. One representative kinase assay out of three is shown. Differences between samples were below 5% in all cases.

Our data are consistent with the hypothesis that mitogen treatment induces a kinase that inactivates Raf-1 by phosphorylating Ser259 and is counteracted by an okadaic acid-sensitive phosphatase. The strength of Raf-1 activation (or the proportion of Raf-1 molecules that can be activated) would depend on the balance between the activity of these two enzymes. Such a regulation would be particularly opportune in the case of Raf-1, whose moderate activation elicits proliferation, while a strong, prolonged Raf-1 signal leads to cell cycle arrest (48, 49). In line with this hypothesis, while this manuscript was in preparation, activated protein kinase B was shown to phosphorylate Ser259 of Raf-1, to suppress the activation of the mitogen-activated protein kinase cascade, and to shift a cell line from cell cycle arrest to proliferation (21).

Raf-1 Forms Complexes with PP2A in Vivo and in Vitro-- Okadaic acid specifically blocked Raf-1 activation at a concentration that selectively inhibits PP2A (47). We therefore examined whether PP2A associated physically with Raf-1. Both the catalytic (PP2AC) and the regulatory (PR65) subunit of the PP2A core enzyme were detected in Raf-1 immunoprecipitates prepared from quiescent as well as CSF-1-treated cells. Neither PP2AC nor PR65 could be detected in precipitates prepared with nonimmune sera (lanes 1 and 2) or with protein A (Fig. 3A). In addition, significant amounts of Raf-1 were present in immunoprecipitates prepared with a monoclonal antibody against PP2AC but not with nonimmune mouse IgG (Fig. 3B), demonstrating the specificity of the interaction. The ubiquitously expressed PP2A core heterodimer binds to different variable subunits of cellular or viral origins, which are involved in regulating its substrate specificity and/or localization. None of the cellular variable subunits tested (p55alpha and -beta , and p72 plus p130) was present in Raf-1 immunoprecipitates (not shown). Consistent findings were obtained in fibroblasts stimulated with EGF (not shown).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Endogenous Raf-1 interacts with PP2A heterodimers in vivo. A, the PP2A core heterodimer is present in Raf-1 immunoprecipitates from quiescent and mitogen-stimulated BAC-1.2F5 cells. Quiescent BAC-1.2F5 cells were stimulated with 6.3 nM mouse recombinant CSF-1 at 37 °C for different times prior to solubilization. Raf-1 immunoprecipitates from 1 mg of whole cell lysates were analyzed by Western blotting with antisera directed against the 36-kDa catalytic subunit of PP2A, PR65alpha , and Raf-1. 25 µg of whole cell lysates (WCL) were loaded as a control. Neither PP2AC nor PR65 were detected in immunoprecipitates prepared using nonimmune rabbit sera (NI) or protein A beads (A) instead of the Raf-1-specific antiserum. The background bands observed in the PP2AC Westerns could also be detected by anti-rabbit antibody alone and represent IgG heavy chains. B, Raf-1 is present in PP2AC immunoprecipitates. BAC-1.2F5 were solubilized, and 1 mg of whole cell lysates were subjected to immunoprecipitation using a monoclonal antibody against PP2AC (PP2AC), nonimmune mouse IgG (NI), or an anti-Raf-1 serum. The immunoprecipitates were analyzed with monoclonal antibodies directed against PP2AC, PR65, or Raf-1.

We next verified the interaction between Raf-1 and the PP2A heterodimer in COS-7 cells transfected with vectors directing the expression of HA-tagged PP2A subunits (Fig. 4A). Anti-HA immunoprecipitates from cells transfected with the HA-tagged PP2AC contained low amounts of endogenous PR65 and Raf-1 (Fig. 4A, lane 1). Anti-HA immunoprecipitates from cells transfected with the HA-PR65, on the other hand, contained significant amounts of endogenous PP2AC subunit and more Raf-1 (Fig. 4A, compare lanes 1 and 2). Therefore, the amount of Raf-1 detected correlated with the amount of heterodimer present in the anti-HA immunoprecipitates. To confirm the specificity of the interaction between the HA-tagged PP2A subunits and Raf-1, we monitored the presence of Raf-1 in anti-HA immunoprecipitates from cells overexpressing HA-ERK (Fig. 4B). Neither endogenous (lane 3) nor overexpressed Raf-1 (lane 4) could be detected in these immunoprecipitates.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   PP2A subunits interact with Raf-1 in transfected COS cells and in vitro. A, Raf-1/PP2A interaction in transiently transfected COS cells. COS-7 cells were transfected by electroporation with plasmids encoding HA-tagged human PP2ACalpha , HA-tagged human PR65alpha , or empty vector. Two days after transfection, the cells were harvested and the HA-tagged subunits of the PP2A heterodimer were immunoprecipitated with an anti-HA antibody. The immunoprecipitates were analyzed by Western blotting with antisera directed against Raf-1, PR65, the 36-kDa catalytic subunit of PP2A (PP2AC), or the HA tag (HA-PR65 and HA-PP2AC). B, lack of Raf-1 interaction with HA-ERK. COS-7 cells were transfected by electroporation with plasmids encoding HA-tagged ERK (pCMV-HA-ERK2) and empty vector or wild type Raf-1. HA or Raf-1 immunoprecipitates were analyzed by Western blotting with antisera directed against Raf-1 or the HA-tag. C, binding of purified PP2A heterodimers, PP2AC, and PR65 to Raf-1 and Raf-1* in vitro. GST (200 ng), GST-Raf-1 (200 ng), and GST-Raf-1* (Raf-1 activated by co-infection of Sf9 cells with baculoviruses encoding v-ras and lck; 100 ng) were immobilized on glutathione-agarose beads and incubated for 3 h at 4 °C with 200 ng of purified core heterodimer (D), PP2AC (C), or recombinant PR65 (R). Complexes were recovered by centrifugation and washed in a buffer containing 0.03% SDS, 0.5 M NaCl prior to electrophoresis and Western blot analysis. 20 ng of purified dimer (D) and PP2AC plus PR65 (C+R) were loaded as a control.

The Raf-1-PP2A complex formation was further analyzed by in vitro reconstitution experiments with purified proteins (Fig. 4C). GST-tagged Raf was expressed in Sf-9 cells alone or in combination with v-Ras plus Lck in order to activate it (Raf*). Raf proteins immobilized on glutathione-Sepharose beads were incubated with PR65, PP2AC, or the heterodimer PR65-PP2AC. Consistent with the lack of effect of mitogens on in vivo complex formation, we did not observe significant differences between PP2A binding to Raf or Raf*. PP2AC displayed only weak binding to Raf-1. In contrast, both PR65 and the core heterodimer associated strongly. Thus, as it is the case for cellular and viral subunits (28), PR65 probably plays the key role in the association between Raf-1 and the PP2A heterodimer. This association, however, is not likely to be direct. Raf-1 does not interact with PR65, PP2AC, or p55 in the yeast two-hybrid system,2 and size fractionation experiments indicate that in vivo Raf-1 and PP2A are part of a large protein complex (data not shown). Additional proteins, and possibly a variable subunit not detected in our experiments, might also be present in small amounts in the purified enzyme preparations used in the GST pull-down experiments and might be facilitating or even mediating the interaction observed in vitro. In this context, a variable subunit of PP2A has been recently shown to positively regulate Ras signaling upstream of raf during vulval development in Caenorhabditis elegans (50).

Conclusion-- Concentrations of okadaic acid that specifically affect PP2A reduced Raf-1 activation, and PP2A was found in Raf-1 immunoprecipitates from quiescent and mitogen-treated cells. Therefore, while an effect of the drug on other phosphatases cannot be formally excluded, PP2A presumably represents the okadaic acid-sensitive phosphatase involved in Raf-1 regulation. Our current working model is that Raf-1-associated PP2A facilitates kinase activation by maintaining Ser259 in a dephosphorylated state and thereby preventing the formation of inactive 14-3-3-Raf-1 complexes (14-18). This may permit the activation of a larger number of Raf-1 molecules and prolong it by counteracting the mitogen-induced kinase (probably protein kinase B) that phosphorylates Ser259. Ultimately, the Ser259 kinase must outpace PP2A to terminate Raf-1 activation. Inhibition of PP2A by okadaic acid has been reported to selectively impair Raf-dependent transformation (51). Furthermore, in genetically dissectable organisms, hypomorphic alleles of PP2A suppress the effects of activated Raf (52) or enhance the loss of function phenotype of Raf mutations (50). On the basis of these results, PP2A might have been considered either a Raf-1 effector or a positive regulator of Raf-1 activation. Our findings provide a mechanistic explanation for these observations. By identifying PP2A as a positive regulator of Raf-1, our data define a new function for this phosphatase and add a new facet to the complexity of Raf-1 regulation.

    ACKNOWLEDGEMENTS

The skillful technical assistance of Julia Katzenbeisser is gratefully acknowledged. We thank Dr. Christopher Marshall (Chester Beatty Laboratories, ICRF, London) for the gift of bacteria expressing GST-ERK-2 and GST-MEK; Prof. Philip Cohen (University of Dundee) for the gift of purified recombinant MEK and mitogen-activated protein kinase; Prof. Jozef Goris, Dr. Patric Turowski, and Dr. Lisa Ballou for providing purified preparations of PP2A heterodimer, PR65alpha , and PP2AC, respectively; and Dr. Jolanda Schreurs (Chiron Corp. Emeryville, CA) for supplying human recombinant CSF-1. We are indebted to Drs. Egon Ogris and Thomas Decker (Vienna Biocenter) for many helpful discussions and for critically reading the manuscript.

    FOOTNOTES

* This work was supported by Austrian Research Fund Grant P12279-MOB (to M. B.), by European Community Grant PL963328 (to M. B., B. A. H., and S. M. D.), and by a grant from the Deutsche Forschungsgemeinschaft (Bonn) (to W. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These two authors contributed equally to this work.

§§ To whom correspondence should be addressed. Tel.: ++431-4277-54607; Fax: ++431-4277-9546; E-mail: manuela@gem.univie.ac.at.

Published, JBC Papers in Press, May 4, 2000, DOI 10.1074/jbc.M003259200

2 J. Rüth, V. Janssens, J. Goris, and M. Baccarini, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; PP2A, protein phosphatase 2A; CSF-1, colony-stimulating factor-1; HA, hemagglutinin; CMV, cytomegalovirus; EGF, epidermal growth factor; GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. (1996) Nat. Med. 2, 668-675
2. Daum, G., Eisenmann-Tappe, I., Fries, H. W., Troppmair, J., and Rapp, U. R. (1994) Trends Biochem. Sci. 19, 474-480
3. Marshall, M. (1995) Mol. Reprod. Dev. 42, 493-499
4. McCormick, F. (1995) Mol. Reprod. Dev. 42, 500-506
5. Diaz, B., Barnard, D., Filson, A., MacDonald, S., King, A., and Marshall, M. (1997) Mol. Cell. Biol. 17, 4509-4516
6. King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M. S. (1998) Nature 396, 180-183
7. Marais, R., Light, Y., Paterson, H. F., and Marshall, C. J. (1995) EMBO J. 14, 3136-3145
8. Mason, C. S., Springer, C. J., Cooper, R. G., Superti-Furga, G., Marshall, C. J., and Marais, R. (1999) EMBO J. 18, 2137-2148
9. Wartmann, M., and Davis, R. J. (1994) J. Biol. Chem. 269, 6695-6701
10. Wartmann, M., Hofer, P., Turowski, P., Saltiel, A. R., and Hynes, N. E. (1997) J. Biol. Chem. 272, 3915-3923
11. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494
12. Morrison, D. K., Heidecker, G., Rapp, U. R., and Copeland, T. D. (1993) J. Biol. Chem. 268, 17309-17316
13. Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996) Cell 84, 889-897
14. Aitken, A. (1996) Trends Cell Biol. 6, 341-347
15. Rommel, C., Radziwill, G., Moelling, K., and Hafen, E. (1997) Mech. Dev. 64, 95-104
16. Tzivion, G., Luo, Z., and Avruch, J. (1998) Nature 394, 88-92
17. Roy, S., McPherson, R. A., Apolloni, A., Yan, J., Lane, A., Clyde-Smith, J., and Hancock, J. F. (1998) Mol. Cell. Biol. 18, 3947-3955
18. Thorson, J. A., Yu, L. W., Hsu, A. L., Shih, N. Y., Graves, P. R., Tanner, J. W., Allen, P. M., Piwnica-Worms, H., and Shaw, A. S. (1998) Mol. Cell. Biol. 18, 5229-5238
19. Mischak, H., Seitz, T., Janosch, P., Eulitz, M., Steen, H., Schellerer, M., Philipp, A., and Kolch, W. (1996) Mol. Cell. Biol. 16, 5409-5418
20. Baek, K. H., Fabian, J. R., Sprenger, F., Morrison, D. K., and Ambrosio, L. (1996) Dev. Biol. 175, 191-204
21. Zimmermann, S., and Moelling, K. (1999) Science 286, 1741-1744
22. Michaud, N. R., Fabian, J. R., Mathes, K. D., and Morrison, D. K. (1995) Mol. Cell. Biol. 15, 3390-3397
23. Wera, S., and Hemmings, B. A. (1995) Biochem. J. 311, 17-29
24. Pallas, D. C., Shahrik, L. K., Martin, B. L., Jaspers, S., Miller, T. B., Brautigan, D. L., and Roberts, T. M. (1990) Cell 60, 167-176
25. Yang, S. I., Lickteig, R. L., Estes, R., Rundell, K., Walter, G., and Mumby, M. C. (1991) Mol. Cell. Biol. 11, 1988-1995
26. Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., and Mumby, M. (1993) Cell 75, 887-897
27. Ruediger, R., Roeckel, D., Fait, J., Bergqvist, A., Magnusson, G., and Walter, G. (1992) Mol. Cell. Biol. 12, 4872-4882
28. Kamibayashi, C., and Mumby, M. C. (1995) Adv. Protein Phosphatases 9, 195-210
29. Westphal, R. S., Anderson, K. A., Means, A. R., and Wadzinski, B. E. (1998) Science 280, 1258-1261
30. Westphal, R. S., Coffee, R. L., Jr., Marotta, A., Pelech, S. L., and Wadzinski, B. E. (1999) J. Biol. Chem. 274, 687-692
31. Heriche, J. K., Lebrin, F., Rabilloud, T., Leroy, D., Chambaz, E. M., and Goldberg, Y. (1997) Science 276, 952-955
32. Morgan, C., Pollard, J. W., and Stanley, E. R. (1987) J. Cell. Physiol. 130, 420-427
33. Stanley, E. R. (1985) Methods Enzymol. 116, 564-587
34. Dilworth, S. M., and Horner, V. P. (1993) J. Virol. 67, 2235-2244
35. Evans, D. R., Myles, T., Hofsteenge, J., and Hemmings, B. A. (1999) J. Biol. Chem. 274, 24038-24046
36. Baccarini, M., Li, W., Sbarba, P. D., and Stanley, E. R. (1991) Receptor 1, 243-259
37. Turowski, P., Fernandez, A., Favre, B., Lamb, N. J., and Hemmings, B. A. (1995) J. Cell Biol. 129, 397-410
38. Hendrix, P., Turowski, P., Mayer-Jaekel, R. E., Goris, J., Hofsteenge, J., Merlevede, W., and Hemmings, B. A. (1993) J. Biol. Chem. 268, 7330-7337
39. Hendrix, P., Mayer-Jackel, R. E., Cron, P., Goris, J., Hofsteenge, J., Merlevede, W., and Hemmings, B. A. (1993) J. Biol. Chem. 268, 15267-15276
40. Kolch, W., Weissinger, E., Mischak, H., Troppmair, J., Showalter, S. D., Lloyd, P., Heidecker, G., and Rapp, U. R. (1990) Oncogene 5, 713-720
41. Alessi, D. R., Cohen, P., Ashworth, A., Cowley, S., Leevers, S. J., and Marshall, C. J. (1995) Methods Enzymol. 255, 279-290
42. Li, S., Janosch, P., Tanji, M., Rosenfeld, G. C., Waymire, J. C., Mischak, H., Kolch, W., and Sedivy, J. M. (1995) EMBO J. 14, 685-696
43. Macdonald, S. G., Crews, C. M., Wu, L., Driller, J., Clark, R., Erikson, R. L., and McCormick, F. (1993) Mol. Cell. Biol. 13, 6615-6620
44. Stone, S. R., Hofsteenge, J., and Hemmings, B. A. (1987) Biochemistry 26, 7215-7220
45. Buscher, D., Hipskind, R. A., Krautwald, S., Reimann, T., and Baccarini, M. (1995) Mol. Cell. Biol. 15, 466-475
46. Krautwald, S., Buscher, D., Kummer, V., Buder, S., and Baccarini, M. (1996) Mol. Cell. Biol. 16, 5955-5963
47. Favre, B., Turowski, P., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 13856-13863
48. Sewing, A., Wiseman, B., Lloyd, A. C., and Land, H. (1997) Mol. Cell. Biol. 17, 5588-5597
49. Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E., and McMahon, M. (1997) Mol. Cell. Biol. 17, 5598-5611
50. Sieburth, D. S., Sundaram, M., Howard, R. M., and Han, M. (1999) Genes Dev. 13, 2562-2569
51. Sakai, R., Ikeda, I., Kitani, H., Fujiki, H., Takaku, F., Rapp, U., Sugimura, T., and Nagao, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9946-9950
52. Wassarman, D. A., Solomon, N. M., Chang, H. C., Karim, F. D., Therrien, M., and Rubin, G. M. (1996) Genes Dev. 10, 272-278


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Zang, J. Gong, L. Luo, J. Zhou, X. Xiang, W. Huang, Q. Huang, X. Luo, M. Olbrot, Y. Peng, et al.
Characterization of Ser338 Phosphorylation for Raf-1 Activation
J. Biol. Chem., November 14, 2008; 283(46): 31429 - 31437.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. M. Thiaville, Y.-X. Pan, A. Gjymishka, C. Zhong, R. J. Kaufman, and M. S. Kilberg
MEK Signaling Is Required for Phosphorylation of eIF2{alpha} following Amino Acid Limitation of HepG2 Human Hepatoma Cells
J. Biol. Chem., April 18, 2008; 283(16): 10848 - 10857.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. R. Junttila, S.-P. Li, and J. Westermarck
Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
FASEB J, April 1, 2008; 22(4): 954 - 965.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. C. Harwood, L. Shu, and P. J. Houghton
mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A
J. Biol. Chem., February 1, 2008; 283(5): 2575 - 2585.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
V. Adler, W. Bowne, J. Michl, K. A. Sookraj, K. Ikram, S. Pestka, L. Izotova, M. Zenilman, F. K. Friedman, Y. Qu, et al.
Site-Specific Phosphorylation of raf in Cells Containing Oncogenic ras-p21 Is Likely Mediated by jun-N-Terminal Kinase
Ann. Clin. Lab. Sci., January 1, 2008; 38(1): 47 - 56.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. von Bulow, S. Dubben, G. Engelhardt, S. Hebel, B. Plumakers, H. Heine, L. Rink, and H. Haase
Zinc-Dependent Suppression of TNF-{alpha} Production Is Mediated by Protein Kinase A-Induced Inhibition of Raf-1, I{kappa}B Kinase beta, and NF-{kappa}B
J. Immunol., September 15, 2007; 179(6): 4180 - 4186.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
I. Nazarenko, R. Schafer, and C. Sers
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells
J. Cell Sci., April 15, 2007; 120(8): 1393 - 1404.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Sun, G. Stoecklin, S. Van Way, V. Hinkovska-Galcheva, R.-F. Guo, P. Anderson, and T. P. Shanley
Tristetraprolin (TTP)-14-3-3 Complex Formation Protects TTP from Dephosphorylation by Protein Phosphatase 2a and Stabilizes Tumor Necrosis Factor-{alpha} mRNA
J. Biol. Chem., February 9, 2007; 282(6): 3766 - 3777.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. Hmitou, S. Druillennec, A. Valluet, C. Peyssonnaux, and A. Eychene
Differential Regulation of B-Raf Isoforms by Phosphorylation and Autoinhibitory Mechanisms
Mol. Cell. Biol., January 1, 2007; 27(1): 31 - 43.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
J. Y. C. Chow and K. E. Barrett
Role of protein phosphatase 2A in calcium-dependent chloride secretion by human colonic epithelial cells
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C452 - C459.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Rodriguez-Viciana, C. Collins, and M. Fried
Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control
PNAS, December 19, 2006; 103(51): 19290 - 19295.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J.-H. Lee, J.-S. Lee, S.-E. Kim, B.-S. Moon, Y.-C. Kim, S.-K. Lee, S.-K. Lee, and K.-Y. Choi
Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway
Mol. Cancer Ther., December 1, 2006; 5(12): 3222 - 3231.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
C. G. Ossum, T. Wulff, and E. K. Hoffmann
Regulation of the mitogen-activated protein kinase p44 ERK activity during anoxia/recovery in rainbow trout hypodermal fibroblasts
J. Exp. Biol., May 1, 2006; 209(9): 1765 - 1776.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
G.-Z. Tao, D. M. Toivola, Q. Zhou, P. Strnad, B. Xu, S. A. Michie, and M. B. Omary
Protein phosphatase-2A associates with and dephosphorylates keratin 8 after hyposmotic stress in a site- and cell-specific manner.
J. Cell Sci., April 1, 2006; 119(Pt 7): 1425 - 1432.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. K. Rushworth, A. D. Hindley, E. O'Neill, and W. Kolch
Regulation and role of raf-1/b-raf heterodimerization.
Mol. Cell. Biol., March 1, 2006; 26(6): 2262 - 2272.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
V. Balan, D. T. Leicht, J. Zhu, K. Balan, A. Kaplun, V. Singh-Gupta, J. Qin, H. Ruan, M. J. Comb, and G. Tzivion
Identification of Novel In Vivo Raf-1 Phosphorylation Sites Mediating Positive Feedback Raf-1 Regulation by Extracellular Signal-regulated Kinase
Mol. Biol. Cell, March 1, 2006; 17(3): 1141 - 1153.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. G. Adams, R. L. Coffee Jr., H. Zhang, S. Pelech, S. Strack, and B. E. Wadzinski
Positive Regulation of Raf1-MEK1/2-ERK1/2 Signaling by Protein Serine/Threonine Phosphatase 2A Holoenzymes
J. Biol. Chem., December 30, 2005; 280(52): 42644 - 42654.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Konopleva, Y. Shi, L. S. Steelman, J. G. Shelton, M. Munsell, F. Marini, T. McQueen, R. Contractor, J. A. McCubrey, and M. Andreeff
Development of a Conditional In vivo Model to Evaluate the Efficacy of Small Molecule Inhibitors for the Treatment of Raf-Transformed Hematopoietic Cells
Cancer Res., November 1, 2005; 65(21): 9962 - 9970.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. J. Van Kanegan, D. G. Adams, B. E. Wadzinski, and S. Strack
Distinct Protein Phosphatase 2A Heterotrimers Modulate Growth Factor Signaling to Extracellular Signal-regulated Kinases and Akt
J. Biol. Chem., October 28, 2005; 280(43): 36029 - 36036.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Ziogas, K. Moelling, and G. Radziwill
CNK1 Is a Scaffold Protein That Regulates Src-mediated Raf-1 Activation
J. Biol. Chem., June 24, 2005; 280(25): 24205 - 24211.
[Abstract] [Full Text] [PDF]


Home page